Welcome to the homepage of LBI-HTA !
The LBI-HTA is an acadmic non-profit institute and belongs to the Ludwig Boltzmann Society. At our website we wish to present our research and give support for health care decision-making. Here all of our reports are available for free. For further information please contact the LBI-HTA team.
At this moment no events are planned. We will inform you on future events.
Tuesday, May 29th 2018, 9:00 AM to 5:30 PM
Gesellschaft der Ärzte
Frankgasse 8, 1090 Vienna
By invitation only
Philosophical Dialogue on 'Individual vs. collective benefit: Can the greatest possible benefit be calculated? Can the individual understand collective benefits?'
This Information is available in German only.
Screening for fetal trisomies 21, 18 and 13 by non-invasive prenatal testing (NIPT). EUnetHTA report
Since several years, numerous new non-invasive prenatal tests (NIPTs) have been available to identify common chromosomal anomalies. Most NIPTs are available for trisomies 21, 18 and 13 and sex chromosome aneuploidies, but many laboratories have expanded their range of analysis to include other trisomies and common microdeletions. The main advantage of NIPT compared to the conventional screening approach is the ease of implementation and non-invasiveness of the assay, as well as the potential reduction in false-positive [FP] results. An introduction of non-invasive genetic testing has ethical, social and organizational implications that need to be considered.
Publication: LBI-HTA Project report No. 103: http://eprints.hta.lbg.ac.at/1153/
Contact: Claudia Wild
We are pleased to introduce our new HSO report.
MammaPrint® Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer. EunetHTA report
MammaPrint® is a test that measures the activity of certain genes within the tumour cells to estimate the likelihood of the tumour to return and spread to other organs, where it becomes incurable. Based on the outcome of MammaPrint®, depending whether the tumour has a low or high risk of returning, and in consultation with the clinician, it can be determined whether or not additional chemotherapy is needed after surgery. This 'gene expression test' is analysing the activity of 70 genes in the breast tumour and claims to be a tumour fingerprint.
Publication: LBI-HTA Project report No.102: http://eprints.hta.lbg.ac.at/1147
Contact: Claudia Wild
Perinatal Care at the threshold of viability Part II: Decision-making at the threshold of viability and ethical challenges at Neonatal Intensive Care Units (NICUs)
Due to the medical advances in neonatal intensive care medicine, the survival rate of premature infants has increased over the last two decades with babies born after 22 weeks of gestation now having a chance of survival. Based on interviews with five heads of Austrian perinatal care centers and a clinical ethicist, this literature review outlines the current evidence on decision-making practices (guidelines, good practice models, and communication strategies) and ethical challenges at the limit of viability.
Publication: LBI-HTA Projekt report No. 97b: http://eprints.hta.lbg.ac.at/1148/
Contact: Michal Stanak
Perinatal care at the threshold of viability; Part I: Systematic Analysis of Outcomes and Resource Needs for Neonatal Intensive Care Units to inform Healthcare Planning
Due to the medical advances in neonatal intensive care medicine, the survival rate of premature infants has increased over the last two decades, with babies born after 22 weeks of gestation now having a chance of survival. In a systematic review, recent data on survival and survival without impairment for extremely preterm infants was collected, as well as literature on resource needs in neonatal intensive care units (NICUs). In addition, interviews with five heads of Austrian perinatal care centers provide insights into the current supply situation in Austrian NICUs.
Publication: LBI-HTA Project report No. 97a: http://eprints.hta.lbg.ac.at/1146/
Contact : Katharina Hawlik